Recruiting
Phase 2

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04164082

Conditions

Bladder Urothelial Carcinoma In Situ

Non-Muscle Invasive Bladder Urothelial Carcinoma

Stage 0a Bladder Cancer AJCC v8

Stage 0is Bladder Cancer AJCC v8

Stage I Bladder Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Computed Tomography

Cystoscopy

Gemcitabine Hydrochloride

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information